326 related articles for article (PubMed ID: 19225113)
21. Intracranial bleeding in acute promyelocytic leukemia treated with arsenic trioxide based regimens is associated with induction mortality but not with relapse.
Kulkarni UP; Selvarajan S; Fouzia NA; Lionel S; Nair SC; Balasubramanian P; Mani T; Abraham A; George B; Mathews V
Blood Cancer J; 2023 Jun; 13(1):94. PubMed ID: 37349334
[No Abstract] [Full Text] [Related]
22. Kidney transplantation in a patient with end stage renal disease after complete remission of acute promyelocytic leukemia.
Chun HJ; Kim SJ; Sun IO; Chung BH; Kim JI; Moon IS; Min WS; Yang CW
J Korean Med Sci; 2012 Jul; 27(7):814-7. PubMed ID: 22787381
[TBL] [Abstract][Full Text] [Related]
23. A Life-Threatening Complication During the Fourth Pregnancy Due to Acute Promyelocytic Leukemia: A Case Report.
Sisnawati IA; Salay K; Fadillah LN; Jazilah I; Mintarjo JA; Billah A; Putra AS; Hersana IDMW; Novita C
Acta Med Indones; 2024 Jan; 56(1):76-83. PubMed ID: 38561886
[TBL] [Abstract][Full Text] [Related]
24. A practical strategy to subcutaneous administered
Liu X; Yin W; Widjaya AS; Yang Y; Liu Y; Jiang Y
Asian J Pharm Sci; 2021 Sep; 16(5):633-642. PubMed ID: 34849168
[TBL] [Abstract][Full Text] [Related]
25. Case Report: Very Late, Atypical Extra-Medullary Relapse in a Patient With Acute Promyelocytic Leukemia (APL) Rescued With a Transplant-Free Approach.
Molica M; Mazzone C; Ottone T; Niscola P; Abruzzese E; Fratoni S; Voso MT; de Fabritiis P
Front Oncol; 2021; 11():699886. PubMed ID: 34268125
[TBL] [Abstract][Full Text] [Related]
26. A case of acute promyelocytic leukemia with pericardial effusion successfully managed with colchicine during ATO administration.
Goto T; Nakamura N; Suzaki T; Shimazu R; Kaneda Y; Ikoma Y; Matsumoto T; Nakamura H; Kanemura N; Shimizu M
Ann Hematol; 2024 Apr; 103(4):1409-1410. PubMed ID: 38376572
[No Abstract] [Full Text] [Related]
27. Gilteritinib Monotherapy as a Transplant Bridging Option for a Patient with
Kobayashi H; Tsutsumi H; Misaki Y; Maekawa T; Inoshita N; Kawamura M; Maseki N
Case Rep Hematol; 2023; 2023():8568587. PubMed ID: 38124780
[TBL] [Abstract][Full Text] [Related]
28. The efficacy and adverse events of arsenic trioxide for the patients with myelodysplastic syndrome: a systematic review and component network meta-analysis.
Huang X; Liu Y; Liu R; Zou X; Yang H
Hematology; 2023 Dec; 28(1):2274149. PubMed ID: 37908176
[TBL] [Abstract][Full Text] [Related]
29. Pseudotumour Cerebri Induced by All-Trans Retinoic Acid: A Case Report.
Ramburuth V; Khalil L
Cureus; 2023 Nov; 15(11):e48520. PubMed ID: 38073920
[TBL] [Abstract][Full Text] [Related]
30. Acute promyelocytic leukemia in children cancer hospital Egypt.
Semary S; Hammad M; Yassin D; El Sharkawy N; Soliman S; Salem S; Ezzat E; Mosa A; Ahmed S
Discov Oncol; 2024 Jun; 15(1):223. PubMed ID: 38861104
[TBL] [Abstract][Full Text] [Related]
31. Negative expression of CD117 predicted inferior OS and PFS in acute promyelocytic leukemia.
Zeng H; He J; Dong HB; Zhou M; Zhang Q; Chen LX; Yuan CY; Jiang RR; Liu JW; Ou-Yang J; Ben Y; Chen B
Int J Lab Hematol; 2024 Jun; ():. PubMed ID: 38874282
[TBL] [Abstract][Full Text] [Related]
32. Low platelet count is potentially the most important contributor to severe bleeding in patients newly diagnosed with acute promyelocytic leukemia.
Song YH; Peng P; Qiao C; Zhang R; Li JY; Lu H
Onco Targets Ther; 2017; 10():4917-4924. PubMed ID: 29062237
[TBL] [Abstract][Full Text] [Related]
33. Oral Arsenic Regimen for APL Deemed "Revolutionary".
Cancer Discov; 2023 Dec; ():OF1. PubMed ID: 38086016
[TBL] [Abstract][Full Text] [Related]
34. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
Lo-Coco F; Avvisati G; Vignetti M; Thiede C; Orlando SM; Iacobelli S; Ferrara F; Fazi P; Cicconi L; Di Bona E; Specchia G; Sica S; Divona M; Levis A; Fiedler W; Cerqui E; Breccia M; Fioritoni G; Salih HR; Cazzola M; Melillo L; Carella AM; Brandts CH; Morra E; von Lilienfeld-Toal M; Hertenstein B; Wattad M; Lübbert M; Hänel M; Schmitz N; Link H; Kropp MG; Rambaldi A; La Nasa G; Luppi M; Ciceri F; Finizio O; Venditti A; Fabbiano F; Döhner K; Sauer M; Ganser A; Amadori S; Mandelli F; Döhner H; Ehninger G; Schlenk RF; Platzbecker U; ; ;
N Engl J Med; 2013 Jul; 369(2):111-21. PubMed ID: 23841729
[TBL] [Abstract][Full Text] [Related]
35. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.
Powell BL; Moser B; Stock W; Gallagher RE; Willman CL; Stone RM; Rowe JM; Coutre S; Feusner JH; Gregory J; Couban S; Appelbaum FR; Tallman MS; Larson RA
Blood; 2010 Nov; 116(19):3751-7. PubMed ID: 20705755
[TBL] [Abstract][Full Text] [Related]
36. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure.
de Thé H; Chen Z
Nat Rev Cancer; 2010 Nov; 10(11):775-83. PubMed ID: 20966922
[TBL] [Abstract][Full Text] [Related]
37. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.
Platzbecker U; Avvisati G; Cicconi L; Thiede C; Paoloni F; Vignetti M; Ferrara F; Divona M; Albano F; Efficace F; Fazi P; Sborgia M; Di Bona E; Breccia M; Borlenghi E; Cairoli R; Rambaldi A; Melillo L; La Nasa G; Fiedler W; Brossart P; Hertenstein B; Salih HR; Wattad M; Lübbert M; Brandts CH; Hänel M; Röllig C; Schmitz N; Link H; Frairia C; Pogliani EM; Fozza C; D'Arco AM; Di Renzo N; Cortelezzi A; Fabbiano F; Döhner K; Ganser A; Döhner H; Amadori S; Mandelli F; Ehninger G; Schlenk RF; Lo-Coco F
J Clin Oncol; 2017 Feb; 35(6):605-612. PubMed ID: 27400939
[TBL] [Abstract][Full Text] [Related]
38. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.
Zhang XW; Yan XJ; Zhou ZR; Yang FF; Wu ZY; Sun HB; Liang WX; Song AX; Lallemand-Breitenbach V; Jeanne M; Zhang QY; Yang HY; Huang QH; Zhou GB; Tong JH; Zhang Y; Wu JH; Hu HY; de Thé H; Chen SJ; Chen Z
Science; 2010 Apr; 328(5975):240-3. PubMed ID: 20378816
[TBL] [Abstract][Full Text] [Related]
39. The DNA binding property of PML/RARA but not the integrity of PML nuclear bodies is indispensable for leukemic transformation.
Liu X; Yuan H; Peres L; Chen S; Chen Z; de The H; Zhou J; Zhu J
PLoS One; 2014; 9(8):e104906. PubMed ID: 25119106
[TBL] [Abstract][Full Text] [Related]
40. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).
Iland HJ; Bradstock K; Supple SG; Catalano A; Collins M; Hertzberg M; Browett P; Grigg A; Firkin F; Hugman A; Reynolds J; Di Iulio J; Tiley C; Taylor K; Filshie R; Seldon M; Taper J; Szer J; Moore J; Bashford J; Seymour JF;
Blood; 2012 Aug; 120(8):1570-80; quiz 1752. PubMed ID: 22715121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
